- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01346046
Evaluation of SCOUT DS in Subjects With Type 2 Diabetes #2 (TCOYD2)
December 3, 2012 updated by: VeraLight, Inc.
An Evaluation of a Noninvasive Diabetes Screening Device in Subjects at the TCOYD Diabetes Conference
The primary objective of the trial is to collect SCOUT DS and Hemoglobin A1c measurements of subjects who have been diagnosed with Type 2 diabetes.
Study Overview
Status
Completed
Conditions
Detailed Description
Previous studies have excluded subjects with Type 2 diabetes.
The primary objective of this study is to correct an imbalance in the disease prevalence of the data set used to develop the SCOUT DS diabetes screening algorithm.
Study Type
Observational
Enrollment (Anticipated)
264
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87102
- Albuquerque Convention Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Attendees of the Taking Control of Your Diabetes Health Fair, Albuquerque Convention Center
Description
Inclusion Criteria:
- Age greater than or equal to 18 years Self-reported diagnosis of type 2 diabetes No Self-reported diagnosis of type 2 diabetes
Exclusion Criteria:
Less than 18 years of age
- Diagnosed with type 1 diabetes
- Known to be pregnant (Self Reported)
- Receiving dialysis or having known renal compromise
- Scars, tattoos, rashes or other disruption/discoloration on the left volar forearm.
- Known to have, or at risk for, photosensitivity reactions ( e.g., sensitive to ultraviolet light, or taking medication known to cause photosensitivity)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Those with Type 2 diabetes
270 subjects with Type 2 diabetes
|
|
Non diabetic
30 healthy subjects
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Continuing validation of SCOUT DS algorithm
Time Frame: 1 day
|
Collect SCOUT DS and Hemoglobin A1c measurements of subjects with Type 2 Diabetes
|
1 day
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Walter Forman, MD, Lovelace Scientific Resources
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2011
Primary Completion (Actual)
August 1, 2011
Study Completion (Actual)
August 1, 2011
Study Registration Dates
First Submitted
April 28, 2011
First Submitted That Met QC Criteria
April 29, 2011
First Posted (Estimate)
May 2, 2011
Study Record Updates
Last Update Posted (Estimate)
December 5, 2012
Last Update Submitted That Met QC Criteria
December 3, 2012
Last Verified
December 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VL-2717
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Non-Insulin Dependent
-
VeraLight, Inc.CompletedDiabetes Mellitus, Non-Insulin DependentUnited States
-
Procter and GambleTerminatedNon-Insulin-dependent Diabetes MellitusUnited States
-
National Center for Complementary and Integrative...CompletedDiabetes Mellitus, Non-Insulin Dependent | Non-Insulin DependentUnited States
-
Inha University HospitalCompletedNon Insulin Dependent Diabetes MellitusKorea, Republic of
-
Merck Sharp & Dohme LLCCompletedDiabetes Mellitus, Non-Insulin-Dependent | Type 2 Diabetes Mellitus, Non Insulin Dependent
-
National Nutrition and Food Technology InstituteCompletedNon Insulin Dependent DiabetesIran, Islamic Republic of
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedDiabetes Mellitus, Type II | Diabetes Mellitus, Non Insulin DependentUnited States, Poland, Bulgaria, India, Malaysia, Romania, Canada, Russian Federation, Argentina, Puerto Rico, Czech Republic, United Kingdom, Mexico
-
Lille Catholic UniversityUniversity Hospital, LilleTerminatedNon-insulin-dependent DiabetesFrance
-
National Nutrition and Food Technology InstituteUnknownNon Insulin Dependent DiabetesIran, Islamic Republic of
-
German Diabetes CenterHeinrich-Heine University, DuesseldorfCompletedObesity | Non-insulin-dependent Diabetes MellitusGermany